UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/599,937	08/21/2007	Anna Cederholm	EPCL:015US/ 10613209	6786	
	7590 06/09/201 Z JAWORSKI L.L.P.	EXAMINER			
600 CONGRES		WEN, SHARON X			
SUITE 2400 AUSTIN, TX 7	8701		ART UNIT	PAPER NUMBER	
			1644		
			NOTIFICATION DATE	DELIVERY MODE	
			06/09/2011	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

aopatent@fulbright.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/599,937	CEDERHOLM ET AL.	
Examiner	Art Unit	
SHARON WEN	1644	

		IIION WEN	1044				
The MAILING DATE of this communication appea	ars o	n the cover sheet with the c	correspondence address				
THE REPLY FILED <u>23 May 2011</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apple for Continued Examination (RCE) in compliance with 37 C periods:	replie: eal (wi	s: (1) an amendment, affidavi ith appeal fee) in compliance	t, or other evidence, which places the with 37 CFR 41.31; or (3) a Request				
a) The period for reply expires <u>3</u> months from the mailing date	of the	final rejection.					
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.							
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL							
 The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exten a Notice of Appeal has been filed, any reply must be filed. AMENDMENTS 	nsion 1	thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since				
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for							
appeal; and/or (d) They present additional claims without canceling a continuation Sheet. (See 37 CFR 1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	corres	ponding number of finally reje					
 4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s): 	21. Se :	ee attached Notice of Non-Col					
6. Newly proposed or amended claim(s) would be all	lowab	le if submitted in a separate,	timely filed amendment canceling the				
non-allowable claim(s). 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 3-5 and 10. Claim(s) withdrawn from consideration: 1,6,8,9 and 11-13.							
AFFIDAVIT OR OTHER EVIDENCE	•						
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).							
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).							
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER							
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.							
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s)13. Other:							
		/Sharon Wen/ Primary Examiner, Art U	nit 1644				
	1						

Continuation of 3. NOTE: Applicant's proposed amendment, if entered, would raise potential issues under New Matter and require new consideration and search under Art.

Continuation of 11. does NOT place the application in condition for allowance because: Applicant's proposed amendment is not entered because it changes the scope of the claimed invention by changing "comprising" to "consisting of" with regards to an active component of the composition being administered. Furthermore, it is noted that the proposed amendment, even if entered, would still not obviate the prior art rejection because it does not exclude a conjugated Annexin V for reasons noted in the previous Office Action, mailed 03/31/2011. Although the prior art taught Annexin V played a binding role in the Annexin V conjugate therapy, it does not dismiss Annexin V as an active component of the therapy because binding is a significant biological activity. Therefore, rejections of record are maintained for reasons of record.